Brimrose Technology Corp

Brimrose Technology Corp, a small-business prime contractor headquartered in Sparks Glencoe, Maryland, develops advanced photonic and electro-optical sensor and imaging systems for defense and health research under Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program vehicles, competing exclusively under total small business set-asides. The company is a for-profit corporate entity with 77 recent federal awards spanning contracts, cooperative agreements, and project grants worth a combined $8.31 billion in potential value, though only $34.6 million has been obligated to date. Brimrose operates as a prime on 96% of its awards; 4% involve sub-grant work under Yale University prime recipients.

Brimrose's core capability portfolio centers on handheld and portable optical imaging and spectroscopy systems, with recurring technical themes in photoacoustic imaging, laser-based detection, millimeter-wave imaging, and optical sensor miniaturization. Representative prime-contract work includes a $1.3 million SBIR Phase II from the Defense Health Agency (awarded September 2025) for development of a non-contact, high-resolution all-optical handheld ultrasound imaging system; a $1.31 million SBIR Phase II from Army Research, Development and Engineering Command (September 2024) for low-cost millimeter-wave imaging using plasma waves in high-mobility transistors; a $1.3 million SBIR Phase II from Defense Health Agency (August 2024) for a speckle-tolerant handheld non-contact vital sign monitor with photonics integrated circuits; and a $1.3 million STTR Phase II from Army RDECOM (September 2023) for polarimetric hyperspectral imaging to counter person-borne improvised explosive devices. Grant work includes a National Institute of Biomedical Imaging and Bioengineering project grant partnering with Johns Hopkins University to develop an ultrasound-neuromodulation and photoacoustic-imaging device for monitoring neonatal brain injury, and a Department of Energy Office of Science grant (CFDA 81.049) for development of doped mercury bromide scintillator materials for nuclear physics research.

Customer concentration is heavily skewed by a single outlier: the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense carries $8.28 billion in combined potential value across just two awards, dominating the portfolio by dollar magnitude. Excluding that outlier, active customers are distributed across research and space agencies. NASA Shared Services Center leads by award count (21 awards, $7.7 million potential value), followed by Army RDECOM (19 awards, $12.4 million), Defense Health Agency (3 awards, $3.9 million), and Army Medical Command (4 awards, $1.8 million). The portfolio also includes smaller awards from the National Science Foundation, Department of Energy Office of Science, and Air Force Research Laboratory. Only one named parent vehicle appears in the source: a single task order under the Joint Enterprise Research Development Acquisition and Production-Procurement vehicle.

Activity has been episodic in recent years — five awards in 2022, seven in 2023, nine in 2024, dropping to two in 2025 and one in 2026 — with five awards (combined potential value $6.6 million) facing ultimate completion within the next twenty-four months and therefore subject to recompete. Work is performed at Brimrose's Maryland facility. The sub-grant footprint is minimal: three sub-awards under Yale University as prime grantee, for which Brimrose provides liaison and standards-development support on an open-science hyperspectral imaging initiative.